Optimizing drug dosing for the treatment of chronic lymphocytic leukemia.
Optimizing drug dosing for the treatment of chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2019 Jun;17(6):330-331 Authors: Jain N PMID: 31437134 [PubMed - in process]
Condition: Chronic Lymphocytic Leukemia Intervention: Drug: Umbralisib Sponsors: H. Lee Moffitt Cancer Center and Research Institute; TG Therapeutics, Inc. Recruiting
We examined publication bias and excess significance bias. 63 articles corresponding to 247 meta-analyses were eligible. Nine meta-analyses were classified to have convincing evidence, and 75 were classified as suggestive evidence. The clinical benefit of immunotherapy was supported by convincing evidence in the following settings: anti-PD-1/PD-L1 monoclonal antibody (mAb) therapy for treating advanced melanoma and non-small cell lung cancer (NSCLC), the combination of rituximab and chemotherapy for treating chronic lymphocytic leukemia and B-cell non-Hodgkin’s lymphoma, adoptive cell immunotherapy for NSCLC, and...
Leukemia, Published online: 14 November 2019; doi:10.1038/s41375-019-0630-6Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy
fao A PMID: 31727770 [PubMed - as supplied by publisher]
Authors: Morris AL, Colbourne T, Kirkpatrick I, Banerji V Abstract Nontraumatic chylous pleural effusions (chylothorax) and pericardial effusions (chylopericardium) are rare. They can, however, accompany intrathoracic malignancies and, most commonly, lymphomas. An association of chronic lymphocytic leukemia (cll) with chylopericardium has rarely been reported. A 68-year-old woman with cll, previously treated with single-agent fludarabine in the community, developed pleuritic chest pain and a new pericardial effusion. Computed tomography (ct) imaging of her chest revealed a large pericardial effusion with progressiv...
Conclusions: More than half the study patients received ibrutinib therapy at a submaximal dose without evidence of increased frequency of toxicities or disease progression. The rate of ibrutinib discontinuation was lower in our cohort than has been reported in other settings. Submaximal ibrutinib dosing will have to be further systematically evaluated. PMID: 31708654 [PubMed - in process]
Publication date: Available online 12 November 2019Source: Pharmacological ResearchAuthor(s): Zhuojun Liu, Jia Liu, Tianming Zhang, Mingxia Shi, Xiaofang Chen, Yun Chen, Jian YuAbstractReceptor tyrosine kinase-like orphan receptor 1 (ROR1) is an onco-embryonic antigen presented on chronic lymphocytic leukemia (CLL), but not on normal adult tissues, which promotes CLL-cell survival. Here, ROR1 was identified as a new client of Heat Shock Protein 90 (HSP90) via a mass spectrometry-based screen for ROR1-associated partners followed by co-immunoprecipitation (co-IP) analysis. A binding motif (ELHHPNIV) on ROR1 for HSP90 was re...
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in United States and has a rapidly evolving treatment paradigm. Two phase III clinical trials demonstrated that inhibition of Burton's tyrosine kinase (BTK) with ibrutinib results in extended progression free survival (PFS) as a first line agent when compared to standard chemoimmunotherapy in both young  and older patients . Similar PFS improvement has been noted in phase III trial with the first line use of B-cell lymphoma 2 (BCL2) inhibitor venetoclax .
Condition: Chronic Lymphocytic Leukemia (CLL) Intervention: Sponsor: AbbVie Not yet recruiting
Contributors : Y Perkarsky ; C M CroceSeries Type : Non-coding RNA profiling by high throughput sequencingOrganism : Homo sapiensWe analyzed small RNA sequencing data from CD5+/CD19+ B cells of a cohort of indolent and aggressive CLL patients compared with CD19+ B-cells of healthy donors.We identified tsRNA signatures in indolent and aggressive CLL vs. normal B-cells; we also found a drastic dysregulation of the expression of mature tRFs in CLL.